Biomarkers in Detection of Hepatitis C Virus Infection
Pathogens. 2024 Apr 17;13(4):331. doi: 10.3390/pathogens13040331.ABSTRACTThe hepatitis C virus (HCV) infection affects 58 million people worldwide. In the United States, the incidence rate of acute hepatitis C has doubled since 2014; during 2021, this increased to 5% from 2020. Acute hepatitis C is defined by any symptom of acute viral hepatitis plus either jaundice or elevated serum alanine aminotransferase (ALT) activity with the detection of HCV RNA, the anti-HCV antibody, or hepatitis C virus antigen(s). However, most patients with acute infection are asymptomatic. In addition, ALT activity and HCV RNA levels can fluct...
Source: Cancer Control - April 26, 2024 Category: Cancer & Oncology Authors: Jungreem Woo Youkyung Choi Source Type: research
Cost effectiveness of hepatitis C direct acting agents
Expert Rev Pharmacoecon Outcomes Res. 2024 Apr 26. doi: 10.1080/14737167.2024.2348053. Online ahead of print.ABSTRACTINTRODUCTION: Introduction of direct acting antivirals (DAA) has transformed treatment of chronic hepatitis C (HCV) and made elimination of HCV an achievable goal set forward by World Health Organization by 2030. Multiple barriers need to be overcome for successful eradication of HCV. Availability of pan-genotypic HCV regimens has decreased the need for genotype testing, but maintained high efficacy associated with DAAs.AREAS COVERED: In this review, we will assess the cost-effectiveness of DAA treatment in ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 26, 2024 Category: Health Management Authors: Akshay Shetty Michelle Lee Julia Valenzuela Sammy Saab Source Type: research
Seroprevalence of anti-SARS-CoV-2 in patients with hepatitis B and C: a pre-vaccination study
This study aims to assess the prevalence of anti-SARS-CoV-2 in hepatitis B and C patients in a pre-vaccination of COVID-19 period. Between March 2020 and January 2021, 199 serum samples from individuals with HBsAg/HBV DNA or anti-HCV/HCV RNA positivity were tested for antibodies (IgM and IgG) against SARS-CoV-2 using Electrochemiluminescent Immunoassay (ECLIA). Among these, 50.3 % (100/199) tested positive for hepatitis C virus infection and 49.7 % (99/199) for hepatitis B virus, confirmed through molecular and serological diagnosis. The anti-SARS-CoV-2 seroprevalence was 24.1 % (48/199) in this population, with 23.23 % (2...
Source: Braz J Infect Dis - April 26, 2024 Category: Infectious Diseases Authors: Lucas Lima da Silva Lia Laura Lewis-Ximenez Monica Magalhaes Figueiredo Vanessa Salete de Paula Livia Melo Villar Source Type: research
Cost effectiveness of hepatitis C direct acting agents
Expert Rev Pharmacoecon Outcomes Res. 2024 Apr 26. doi: 10.1080/14737167.2024.2348053. Online ahead of print.ABSTRACTINTRODUCTION: Introduction of direct acting antivirals (DAA) has transformed treatment of chronic hepatitis C (HCV) and made elimination of HCV an achievable goal set forward by World Health Organization by 2030. Multiple barriers need to be overcome for successful eradication of HCV. Availability of pan-genotypic HCV regimens has decreased the need for genotype testing, but maintained high efficacy associated with DAAs.AREAS COVERED: In this review, we will assess the cost-effectiveness of DAA treatment in ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 26, 2024 Category: Health Management Authors: Akshay Shetty Michelle Lee Julia Valenzuela Sammy Saab Source Type: research
Seroprevalence of anti-SARS-CoV-2 in patients with hepatitis B and C: a pre-vaccination study
This study aims to assess the prevalence of anti-SARS-CoV-2 in hepatitis B and C patients in a pre-vaccination of COVID-19 period. Between March 2020 and January 2021, 199 serum samples from individuals with HBsAg/HBV DNA or anti-HCV/HCV RNA positivity were tested for antibodies (IgM and IgG) against SARS-CoV-2 using Electrochemiluminescent Immunoassay (ECLIA). Among these, 50.3 % (100/199) tested positive for hepatitis C virus infection and 49.7 % (99/199) for hepatitis B virus, confirmed through molecular and serological diagnosis. The anti-SARS-CoV-2 seroprevalence was 24.1 % (48/199) in this population, with 23.23 % (2...
Source: Braz J Infect Dis - April 26, 2024 Category: Infectious Diseases Authors: Lucas Lima da Silva Lia Laura Lewis-Ximenez Monica Magalhaes Figueiredo Vanessa Salete de Paula Livia Melo Villar Source Type: research
Viruses, Vol. 16, Pages 682: Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)
unetto
Anna Linda Zignego
Carmine Coppola
Andrea Iannone
Elisa Biliotti
Elena Rosselli Del Turco
Marco Massari
Anna Licata
Francesco Barbaro
Marcello Persico
Filomena Morisco
Maurizio Pompili
Federica Cerini
Massimo Puoti
Teresa Santantonio
Antonio Craxì
Loreta A. Kondili
Liliana Chemello Investigators
on behalf of PITER Collaborating Investigators on behalf of PITER Collaborating Investigators
The treatment of hepatitis C virus (HCV) with direct-acting antivirals (DAA) leads to high sustained virological response (SVR) rates, but hepatocellular carcinoma (HCC) risk persists in peop...
Source: Viruses - April 26, 2024 Category: Virology Authors: Maria Giovanna Quaranta Luisa Cavalletto Francesco Paolo Russo Vincenza Calvaruso Luigina Ferrigno Alberto Zanetto Benedetta Mattioli Roberta D ’Ambrosio Valentina Panetta Giuseppina Brancaccio Giovanni Raimondo Maurizia Rossana Brunetto Anna Linda Zign Tags: Article Source Type: research
Hepatitis C treatment outcomes among people who inject drugs experiencing unstable versus stable housing: Systematic review and meta-analysis
ConclusionsAmong PWID, unstable housing appears to be a barrier to HCV treatment initiation; however, the existing data is limited for treatment initiation and the other outcomes we examined. There is a need for more informative studies to better understand HCV treatment among those with unstable housing. Specifically, future studies should better define housing status beyond a binary, static measure to capture the nuances and complexity of housing and its subsequent impact on HCV treatment. Additionally, researchers should meaningfully consider whether the outcome(s) of interest are being accurately measured for individua...
Source: PLoS One - April 26, 2024 Category: Biomedical Science Authors: Sarah Kimball Source Type: research
Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review
CONCLUSION: Although, studies have shown that HCV genotype-3 infection is an independent risk factor for end-stage liver disease, HCC, and liver-related death, there is a lack of evidence for specific risk factors for HCC secondary to HCV genotype-3. Only cirrhosis and age have demonstrated an association; however, the number of studies is very small, and more research is required to investigate risk factors for HCC secondary to HCV genotype-3.PMID:38660636 | PMC:PMC11037048 | DOI:10.4251/wjgo.v16.i4.1596 (Source: Cancer Control)
Source: Cancer Control - April 25, 2024 Category: Cancer & Oncology Authors: Hamzah Z Farooq Michael James Jane Abbott Patrick Oyibo Pip Divall Naheed Choudhry Graham R Foster Source Type: research
Development and validation of a nomogram for assessing hepatocellular carcinoma risk after SVR in hepatitis C patients with advanced fibrosis and cirrhosis
Hepatitis C patients with advanced fibrosis or cirrhosis are at high risk of developing hepatocellular carcinoma (HCC), even after sustained virological response (SVR). Clinical recommendations impose a signif... (Source: Infectious Agents and Cancer)
Source: Infectious Agents and Cancer - April 25, 2024 Category: Cancer & Oncology Authors: Shanshan Xu, Lixia Qiu, Liang Xu, Yali Liu and Jing Zhang Tags: Research Source Type: research
Assessment of fatigue and its impact in chronic liver disease
Patient reported outcomes (PROs) such as health related quality of life (HRQL) are important outcome measures for patients with chronic liver diseases (CLDs). Presence of cirrhosis and advanced liver disease have been associated with worsened HRQL and fatigue. On the other hand, some patients with earlier stages of CLD such as primary biliary cholangitis (PBC), chronic hepatitis C viral infection (HCV) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), also experience fatigue causing PRO impairment. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 24, 2024 Category: Gastroenterology Authors: Zobair M. Younossi, Andreas E. Kremer, Mark G. Swain, David Jones, Christopher Bowlus, Michael Trauner, Linda Henry, Lynn Gerber Tags: Research Article Source Type: research
Animal hepacivirus models for hepatitis C virus immune responses and pathology
Chronic HCV infection is a leading cause of cirrhosis and hepatocellular carcinoma. While curable with antiviral therapy, a vaccine is essential for HCV containment and eradication. Vaccine development ideally requires immunocompetent animal models, and in vitro systems for assessment of neutralising antibodies (nAbs). Engineered mouse models supporting HCV infection and replication are available but have blunted immune responses, limiting their suitability for vaccine studies. HCV incurred intrahepatic pathology also remains understudied due to the inaccessibility of human liver samples. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 24, 2024 Category: Gastroenterology Authors: Matthew J. Kennedy, Sonja Fernbach, Troels K.H. Scheel Tags: Hepatology Snapshot Source Type: research
Viruses, Vol. 16, Pages 655: Impact of the COVID-19 Pandemic on Hepatitis C Treatment Initiation in British Columbia, Canada: An Interrupted Time Series Study
n
Naveed Zafar Janjua
We investigated the impacts of the COVID-19 pandemic on hepatitis C (HCV) treatment initiation, including by birth cohort and injection drug use status, in British Columbia (BC), Canada. Using population data from the BC COVID-19 Cohort, we conducted interrupted time series analyses, estimating changes in HCV treatment initiation following the introduction of pandemic-related policies in March 2020. The study included a pre-policy period (April 2018 to March 2020) and three follow-up periods (April to December 2020, January to December 2021, and January to December 2022). The level of HCV treatm...
Source: Viruses - April 23, 2024 Category: Virology Authors: Richard L. Morrow Mawuena Binka Julia Li Mike Irvine Sofia R. Bartlett Stanley Wong Dahn Jeong Jean Damascene Makuza Jason Wong Amanda Yu Mel Krajden Naveed Zafar Janjua Tags: Article Source Type: research
Statewide Survey of Primary Care and Subspecialty Providers on Hepatocellular Carcinoma Risk-Stratification and Surveillance Practices
ConclusionsIn this statewide survey, there were great knowledge gaps in HCC surveillance among PCPs and most respondents expressed interest in strategies to increase appropriate HCC surveillance. (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - April 23, 2024 Category: Gastroenterology Source Type: research
Shared genetic factors and causal association between chronic hepatitis C infection and diffuse large B cell lymphoma
Epidemiological research and systematic meta-analyses indicate a higher risk of B-cell lymphomas in patients with chronic hepatitis C virus (HCV) compared to non-infected individuals. However, the genetic link... (Source: Infectious Agents and Cancer)
Source: Infectious Agents and Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Leihua Fu, Jieni Yu, Zhe Chen, Feidan Gao, Zhijian Zhang, Jiaping Fu, Weiying Feng, Pan Hong and Jing Jin Tags: Research Source Type: research
Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
This study ’s purpose was to evaluate AAC and liver-related death in a cohort of Veterans with chronic liver disease (CLD).MethodsWe utilized the VISN 10 CLD cohort, a regional cohort of Veterans with the three forms of CLD: NAFLD, hepatitis C (HCV), alcohol-associated (ETOH), seen between 2008 and 2014, with abdominal CT scans (n = 3604). Associations between MAC and cirrhosis development, liver decompensation, liver-related death, and overall death were evaluated with Cox proportional hazard models.ResultsThe full cohort demonstrated strong associations of MAC and cirrhosis after adjustment: HR 2.13 (95% CI 1.63, 2.7...
Source: Digestive Diseases and Sciences - April 23, 2024 Category: Gastroenterology Source Type: research
